Histology
Carcinoma of Unknown Primary
CI-CAN-00002109Explore in graph →
4,156 active trials54 approved drugs532 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00002109Explore in graph →
Clinical trials
14,232 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,893)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04897542 | Gallium-68 NODAGA-JR11 PECT/CT in Neuroendocrine Tumors | unknown | Early Phase 1 | 100 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Sep 18, 2023 | clinicaltrials |
| NCT06041464 | Study of HLA-DR in Cell Cultures Isolated From Primary Squamous Cell Carcinoma | unknown | — | 4 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 18, 2023 |
| clinicaltrials |
| NCT06039280 | Comparison of Dexamethasone and N Acetylcysteine (NAC) Versus N Acetylcysteine (NAC) Alone in the Prevention of Post Embolization Syndrome in Patients With Hepatocellular Carcinoma Following Transarterial Chemoembolization. | unknown | N/A | 150 | Institute of Liver and Biliary Sciences, IndiaOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT05992584 | Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC | unknown | Phase 2 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT06001567 | Avatrombopag for HCC Patients With Thrombocytopenia Who Intend to Undergo TACE and/or HAIC | unknown | Phase 2 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT03447951 | A Study of PTS100 in Primary HCC Patients(OASES) | unknown | Phase 2 | 33 | Gongwin Biopharm Co., Ltd.INDUSTRY | 1 | Sep 13, 2023 | clinicaltrials |
| NCT05371873 | A Study of Chromosomal Abnormalities as a Predictor of Staging and Prognosis in Patients With Liver Cancer | unknown | — | 250 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT05448222 | Effect of Sarcopenia on Hepatocellular Carcinoma(HCC) After Systemic Therapies | unknown | — | 300 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT05907824 | Long-term Prognosis for Non-functional Neuroendocrine Tumors of the Pancreatic Body and Tail ≤ 3cm | unknown | — | 800 | Fudan UniversityOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT06034977 | Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 120 | Chang Gung Memorial HospitalOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT05990231 | Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy | unknown | Phase 2 | 35 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT06031480 | Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors(FAITH) | unknown | Phase 2 | 55 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT06029829 | The Clinical Significance of Peripheral Blood T Lymphocyte PD-1 Expression and T Cell Subset Distribution. | unknown | Phase 2 | 60 | Xin-Hua XuOTHER | 1 | Sep 8, 2023 | clinicaltrials |
| NCT06023147 | A Real-world Study of the Short-term Efficacy and Safety of E-TACE in Patients With Hepatocellular Carcinoma (HCC) | unknown | N/A | 298 | Xuhua DuanOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT06023875 | Neoadjuvant Cadonilimab in Combination With Cisplatin and Nab-paclitaxel in Resectable Head and Neck Squamous Cell Carcinoma(NCCCNRHNSCC) | unknown | Phase 2 | 30 | Xuekui LiuOTHER | 1 | Sep 5, 2023 | clinicaltrials |
| NCT04852211 | Laparoscopic Versus Open Major Hepatectomy for HCC Hepatectomy for Hepatocellular Carcinoma(AP-LAPO) | unknown | N/A | 212 | Chinese University of Hong KongOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT05451576 | Sodium Selenite Supplementation in Patients With Head and Neck Cancer | unknown | N/A | 60 | Chang Gung Memorial HospitalOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT05534854 | Frequency, Clinical Phenotype and Genetic Analysis of Heritable Kidney Cancer Syndromes | unknown | — | 500 | RenJi HospitalOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT05932511 | Topical Ascorbic Acid for Treatment of Squamous Cell Skin Cancer | unknown | Early Phase 1 | 15 | Center for Biomedical Research, Inc.INDUSTRY | 1 | Aug 30, 2023 | clinicaltrials |
| NCT06016699 | Immunological Function After Radiation With Either Proton or Photon Therapy(PRO-IMMUNO) | unknown | — | 40 | University Medical Center GroningenOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT06017141 | Inhalational or Intravenous Anesthesia During Surgery for Patients With Colon Cancer, VIVA Study | unknown | Phase 2 | 80 | University of Kansas Medical CenterOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT06016400 | Using Vitamin D to Reduce Oral Mucosal Inflammation in Chemotherapy Patients With Oral Squamous Cell Carcinoma | unknown | Phase 2 / Phase 3 | 412 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT06011993 | Real-world Analysis on the Efficacy and Safety of Neoadjuvant Therapy for Head and Neck Squamous Cell Carcinoma （neoHNSCC） | unknown | — | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 25, 2023 | clinicaltrials |
| NCT05681949 | Therapeutic Assistance and Decision-making Algorithms in Hepatobiliary Tumor Boards(ADBoard) | unknown | N/A | 1,200 | Charite University, Berlin, GermanyOTHER | 1 | Aug 24, 2023 | clinicaltrials |
| NCT06009224 | The Effect of ERAS on Pancreaticoduodenectomy (v2.0) | unknown | N/A | 334 | Asan Medical CenterOTHER | 1 | Aug 24, 2023 | clinicaltrials |
| NCT06010212 | Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma | unknown | Phase 1 / Phase 2 | 36 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Aug 24, 2023 | clinicaltrials |
| NCT03731923 | Abbreviated MRI for HCC Surveillance | unknown | N/A | 257 | Seoul National University HospitalOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05420519 | Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer | unknown | Phase 1 | 24 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05420545 | A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors | unknown | Phase 1 | 36 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05468190 | A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T | unknown | Phase 1 | 48 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05610293 | T1 Squamous Cell Carcinomas of the Lip | unknown | — | 300 | Maastricht University Medical CenterOTHER | 1 | Aug 16, 2023 | clinicaltrials |
| NCT05845632 | Time to Treatment and Disease-free Survival of Patients With High-risk Head-neck Cutaneous Squamous Cell Carcinoma | unknown | — | 965 | Maastricht University Medical CenterOTHER | 1 | Aug 16, 2023 | clinicaltrials |
| NCT04135690 | HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial | unknown | Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT05992610 | Induction Treatment in SCC of the Head and Neck Region - Concomitant Chemotherapy and Low-dose Radiotherapy(iCHRTL) | unknown | N/A | 40 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT03961698 | Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma(MARIO-3) | unknown | Phase 2 | 91 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 14, 2023 | clinicaltrials |
| NCT05902455 | Differential Mobility Spectrometry (DMS) Based Oral Tumor Analysis | unknown | — | 40 | Tampere University HospitalOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT05985187 | Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer. | unknown | Phase 3 | 412 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 14, 2023 | clinicaltrials |
| NCT05985577 | Mechanism of Gastric Signet Ring Cell Carcinoma Based on Microproteomics | unknown | — | 300 | Zhejiang Cancer HospitalOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT05987514 | Multimodal Ultrasound and Hepatocellular Response to Local Treatments | unknown | N/A | 50 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT05235906 | A Phase II Clinical Study of Surufatinib Combined With Sintilimab in the Treatment of Advanced Gastric Cancer | unknown | Phase 2 | 61 | Sun Yat-sen UniversityOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT05982834 | Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC | unknown | Phase 1 / Phase 2 | 43 | Fudan UniversityOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT04297995 | Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors | unknown | Phase 2 | 131 | Shanghai Henlius BiotechINDUSTRY | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05886140 | Carrilizumab Combined With White Purple for Squamous Cell Carcinoma of Skin | unknown | N/A | 24 | Henan Cancer HospitalOTHER_GOV | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05981066 | A Clinical Study of mRNA Vaccine (ABOR2014/IPM511) in Patients With Advanced Hepatocellular Carcinoma | unknown | N/A | 48 | Peking Union Medical College HospitalOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05973968 | Surufatinib in G3 Neuroendocrine Tumors | unknown | — | 32 | Qilu Hospital of Shandong UniversityOTHER | 0 | Aug 4, 2023 | clinicaltrials |
| NCT05975944 | Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 49 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03619668 | Chemo-radiotherapy as Main Treatment Strategy for Rectal Cancer. Can we Provide a More Precise and Effective Treatment(AMPERE) | unknown | — | 16 | Aalborg University HospitalOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT03790553 | Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal Carcinoma | unknown | Phase 3 | 646 | Fudan UniversityOTHER | 1 | Aug 3, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Sep 18, 2023source: clinicaltrials